Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1995 Oct;69(10):6289–6296. doi: 10.1128/jvi.69.10.6289-6296.1995

Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).

E G Hulskotte 1, A M Geretti 1, K H Siebelink 1, G van Amerongen 1, M P Cranage 1, E W Rud 1, S G Norley 1, P de Vries 1, A D Osterhaus 1
PMCID: PMC189527  PMID: 7666529

Abstract

To gain further insight into the ability of subunit vaccines to protect monkeys from experimental infection with simian immunodeficiency virus (SIV), two groups of cynomolgus macaques were immunized with either recombinant SIVmac32H-derived envelope glycoproteins (Env) incorporated into immune-stimulating complexes (iscoms) (group A) or with these SIV Env iscoms in combination with p27gag iscoms and three Nef lipopeptides (group B). Four monkeys immunized with recombinant feline immunodeficiency virus Env iscoms served as controls (group C). Animals were immunized intramuscularly at weeks 0, 4, 10, and 16. Two weeks after the last immunization, monkeys were challenged intravenously with 50 monkey 50% infectious doses of virus derived from the J5 molecular clone of SIVmac32H propagated in monkey peripheral blood mononuclear cells. High titers of SIV-neutralizing antibodies were induced in the monkeys of groups A and B. In addition, p27gag-specific antibodies were detected in the monkeys of group B. Vaccine-induced cytotoxic-T-lymphocyte precursors against Env, Gag, and Nef were detected on the day of challenge in the monkeys of group B. Env-specific cytotoxic-T-lymphocyte precursors were detected in one monkey from group A. In spite of the observed antibody and T-cell responses, none of the monkeys was protected from experimental infection. In addition, longitudinal determination of cell-associated virus loads at weeks 2, 4, 6, 9, and 12 postchallenge revealed no significant differences between vaccinated and control monkeys. These findings illustrate the need to clarify the roles of the different arms of the immune system in conferring protection against primate lentivirus infections.

Full Text

The Full Text of this article is available as a PDF (269.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad S., Lohman B., Marthas M., Giavedoni L., el-Amad Z., Haigwood N. L., Scandella C. J., Gardner M. B., Luciw P. A., Yilma T. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1994 Feb;10(2):195–204. doi: 10.1089/aid.1994.10.195. [DOI] [PubMed] [Google Scholar]
  2. Andeweg A. C., Groenink M., Leeflang P., de Goede R. E., Osterhaus A. D., Tersmette M., Bosch M. L. Genetic and functional analysis of a set of HIV-1 envelope genes obtained from biological clones with varying syncytium-inducing capacities. AIDS Res Hum Retroviruses. 1992 Oct;8(10):1803–1813. doi: 10.1089/aid.1992.8.1803. [DOI] [PubMed] [Google Scholar]
  3. Arthur L. O., Bess J. W., Jr, Sowder R. C., 2nd, Benveniste R. E., Mann D. L., Chermann J. C., Henderson L. E. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science. 1992 Dec 18;258(5090):1935–1938. doi: 10.1126/science.1470916. [DOI] [PubMed] [Google Scholar]
  4. Baldinotti F., Matteucci D., Mazzetti P., Giannelli C., Bandecchi P., Tozzini F., Bendinelli M. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol. 1994 Jul;68(7):4572–4579. doi: 10.1128/jvi.68.7.4572-4579.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bos E. S., van der Doelen A. A., van Rooy N., Schuurs A. H. 3,3',5,5' - Tetramethylbenzidine as an Ames test negative chromogen for horse-radish peroxidase in enzyme-immunoassay. J Immunoassay. 1981;2(3-4):187–204. doi: 10.1080/15321818108056977. [DOI] [PubMed] [Google Scholar]
  6. Bourgault I., Chirat F., Tartar A., Lévy J. P., Guillet J. G., Venet A. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides. J Immunol. 1994 Mar 1;152(5):2530–2537. [PubMed] [Google Scholar]
  7. Bourgault I., Venet A., Levy J. P. Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes. J Virol. 1992 Feb;66(2):750–756. doi: 10.1128/jvi.66.2.750-756.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bourgault I., Villefroy P., Beyer C., Aubertin A. M., Levy J. P., Venet A. Cytotoxic T-cell response and AIDS-free survival in simian immunodeficiency virus-infected macaques. AIDS. 1993 Nov;7 (Suppl 2):S73–S79. doi: 10.1097/00002030-199311002-00015. [DOI] [PubMed] [Google Scholar]
  9. Buseyne F., Rivière Y. HIV-specific CD8+ T-cell immune responses and viral replication. AIDS. 1993 Nov;7 (Suppl 2):S81–S85. doi: 10.1097/00002030-199311002-00016. [DOI] [PubMed] [Google Scholar]
  10. Carlson J. R., McGraw T. P., Keddie E., Yee J. L., Rosenthal A., Langlois A. J., Dickover R., Donovan R., Luciw P. A., Jennings M. B. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1239–1246. doi: 10.1089/aid.1990.6.1239. [DOI] [PubMed] [Google Scholar]
  11. Chen Z. W., Yamamoto H., Watkins D. I., Levinson G., Letvin N. L. Predominant use of a T-cell receptor V beta gene family in simian immunodeficiency virus Gag-specific cytotoxic T lymphocytes in a rhesus monkey. J Virol. 1992 Jun;66(6):3913–3917. doi: 10.1128/jvi.66.6.3913-3917.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cranage M. P., Polyanskaya N., McBride B., Cook N., Ashworth L. A., Dennis M., Baskerville A., Greenaway P. J., Corcoran T., Kitchin P. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1993 Jan;9(1):13–22. doi: 10.1089/aid.1993.9.13. [DOI] [PubMed] [Google Scholar]
  13. Cranage M., Stott J., Mills K., Ashworth T., Taffs F., Farrar G., Chan L., Dennis M., Putkonen P., Biberfeld G. Vaccine studies with the 32H reisolate of SIVmac251: an overview. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1479–1481. doi: 10.1089/aid.1992.8.1479. [DOI] [PubMed] [Google Scholar]
  14. Culmann B., Gomard E., Kiény M. P., Guy B., Dreyfus F., Saimot A. G., Sereni D., Lévy J. P. An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur J Immunol. 1989 Dec;19(12):2383–2386. doi: 10.1002/eji.1830191231. [DOI] [PubMed] [Google Scholar]
  15. Culmann B., Gomard E., Kiény M. P., Guy B., Dreyfus F., Saimot A. G., Sereni D., Sicard D., Lévy J. P. Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. J Immunol. 1991 Mar 1;146(5):1560–1565. [PubMed] [Google Scholar]
  16. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  17. Deres K., Schild H., Wiesmüller K. H., Jung G., Rammensee H. G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989 Nov 30;342(6249):561–564. doi: 10.1038/342561a0. [DOI] [PubMed] [Google Scholar]
  18. Desrosiers R. C., Wyand M. S., Kodama T., Ringler D. J., Arthur L. O., Sehgal P. K., Letvin N. L., King N. W., Daniel M. D. Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6353–6357. doi: 10.1073/pnas.86.16.6353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fields C. G., Lloyd D. H., Macdonald R. L., Otteson K. M., Noble R. L. HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res. 1991 Mar-Apr;4(2):95–101. [PubMed] [Google Scholar]
  20. Giavedoni L. D., Planelles V., Haigwood N. L., Ahmad S., Kluge J. D., Marthas M. L., Gardner M. B., Luciw P. A., Yilma T. D. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol. 1993 Jan;67(1):577–583. doi: 10.1128/jvi.67.1.577-583.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Heeney J. L., de Vries P., Dubbes R., Koornstra W., Niphuis H., ten Haaft P., Boes J., Dings M. E., Morein B., Osterhaus A. D. Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines. J Med Primatol. 1992 Feb-May;21(2-3):126–130. [PubMed] [Google Scholar]
  22. Heeney J. L., van Els C., de Vries P., ten Haaft P., Otting N., Koornstra W., Boes J., Dubbes R., Niphuis H., Dings M. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Exp Med. 1994 Aug 1;180(2):769–774. doi: 10.1084/jem.180.2.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hu S. L., Abrams K., Barber G. N., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R., Benveniste R. E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992 Jan 24;255(5043):456–459. doi: 10.1126/science.1531159. [DOI] [PubMed] [Google Scholar]
  24. Israel Z. R., Edmonson P. F., Maul D. H., O'Neil S. P., Mossman S. P., Thiriart C., Fabry L., Van Opstal O., Bruck C., Bex F. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol. 1994 Mar;68(3):1843–1853. doi: 10.1128/jvi.68.3.1843-1853.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Javaherian K., Langlois A. J., Schmidt S., Kaufmann M., Cates N., Langedijk J. P., Meloen R. H., Desrosiers R. C., Burns D. P., Bolognesi D. P. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418–1422. doi: 10.1073/pnas.89.4.1418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Johnson P. R., Montefiori D. C., Goldstein S., Hamm T. E., Zhou J., Kitov S., Haigwood N. L., Misher L., London W. T., Gerin J. L. Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1501–1505. doi: 10.1089/aid.1992.8.1501. [DOI] [PubMed] [Google Scholar]
  27. Johnson P. R., Montefiori D. C., Goldstein S., Hamm T. E., Zhou J., Kitov S., Haigwood N. L., Misher L., London W. T., Gerin J. L. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2175–2179. doi: 10.1073/pnas.89.6.2175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Johnson R. P., Walker B. D. Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural proteins. Curr Top Microbiol Immunol. 1994;189:35–63. doi: 10.1007/978-3-642-78530-6_3. [DOI] [PubMed] [Google Scholar]
  29. Kalams S. A., Johnson R. P., Trocha A. K., Dynan M. J., Ngo H. S., D'Aquila R. T., Kurnick J. T., Walker B. D. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J Exp Med. 1994 Apr 1;179(4):1261–1271. doi: 10.1084/jem.179.4.1261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Klein M. R., van Baalen C. A., Holwerda A. M., Kerkhof Garde S. R., Bende R. J., Keet I. P., Eeftinck-Schattenkerk J. K., Osterhaus A. D., Schuitemaker H., Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 1995 Apr 1;181(4):1365–1372. doi: 10.1084/jem.181.4.1365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994 Jul;68(7):4650–4655. doi: 10.1128/jvi.68.7.4650-4655.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lohman B. L., McChesney M. B., Miller C. J., McGowan E., Joye S. M., Van Rompay K. K., Reay E., Antipa L., Pedersen N. C., Marthas M. L. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 1994 Nov;68(11):7021–7029. doi: 10.1128/jvi.68.11.7021-7029.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Martinon F., Gras-Masse H., Boutillon C., Chirat F., Deprez B., Guillet J. G., Gomard E., Tartar A., Levy J. P. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol. 1992 Nov 15;149(10):3416–3422. [PubMed] [Google Scholar]
  34. Monaco J. J. A molecular model of MHC class-I-restricted antigen processing. Immunol Today. 1992 May;13(5):173–179. doi: 10.1016/0167-5699(92)90122-N. [DOI] [PubMed] [Google Scholar]
  35. Moss P. A., Rosenberg W. M., Zintzaras E., Bell J. I. Characterization of the human T cell receptor alpha-chain repertoire and demonstration of a genetic influence on V alpha usage. Eur J Immunol. 1993 May;23(5):1153–1159. doi: 10.1002/eji.1830230526. [DOI] [PubMed] [Google Scholar]
  36. Mowat A. M., Maloy K. J., Donachie A. M. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology. 1993 Dec;80(4):527–534. [PMC free article] [PubMed] [Google Scholar]
  37. Murphey-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin G. B., Zhang J. Y., Putney S. D. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989 Dec 8;246(4935):1293–1297. doi: 10.1126/science.2555923. [DOI] [PubMed] [Google Scholar]
  38. Murphey-Corb M., Montelaro R. C., Miller M. A., West M., Martin L. N., Davison-Fairburn B., Ohkawa S., Baskin G. B., Zhang J. Y., Miller G. B. Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS. 1991 Jun;5(6):655–662. doi: 10.1097/00002030-199106000-00003. [DOI] [PubMed] [Google Scholar]
  39. Osterhaus A., de Vries P., Heeney J. AIDS vaccine developments. Nature. 1992 Feb 20;355(6362):684–685. doi: 10.1038/355684b0. [DOI] [PubMed] [Google Scholar]
  40. Putkonen P., Björling E., Akerblom L., Thorstensson R., Lövgren K., Benthin L., Chiodi F., Morein B., Biberfeld G., Norrby E. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J Acquir Immune Defic Syndr. 1994 Jun;7(6):551–559. [PubMed] [Google Scholar]
  41. Rabin H., Neubauer R. H., Hopkins R. F., 3rd, Dzhikidze E. K., Shevtsova Z. V., Lapin B. A. Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease. Intervirology. 1977;8(4):240–249. doi: 10.1159/000148899. [DOI] [PubMed] [Google Scholar]
  42. Rimmelzwaan G. F., Siebelink K. H., Huisman R. C., Moss B., Francis M. J., Osterhaus A. D. Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. J Gen Virol. 1994 Aug;75(Pt 8):2097–2102. doi: 10.1099/0022-1317-75-8-2097. [DOI] [PubMed] [Google Scholar]
  43. Riviere Y., Tanneau-Salvadori F., Regnault A., Lopez O., Sansonetti P., Guy B., Kieny M. P., Fournel J. J., Montagnier L. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol. 1989 May;63(5):2270–2277. doi: 10.1128/jvi.63.5.2270-2277.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rud E. W., Cranage M., Yon J., Quirk J., Ogilvie L., Cook N., Webster S., Dennis M., Clarke B. E. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol. 1994 Mar;75(Pt 3):529–543. doi: 10.1099/0022-1317-75-3-529. [DOI] [PubMed] [Google Scholar]
  45. Sawyer L. S., Wrin M. T., Crawford-Miksza L., Potts B., Wu Y., Weber P. A., Alfonso R. D., Hanson C. V. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol. 1994 Mar;68(3):1342–1349. doi: 10.1128/jvi.68.3.1342-1349.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Scherle P. A., Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med. 1986 Oct 1;164(4):1114–1128. doi: 10.1084/jem.164.4.1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Schild H., Deres K., Wiesmüller K. H., Jung G., Rammensee H. G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol. 1991 Nov;21(11):2649–2654. doi: 10.1002/eji.1830211102. [DOI] [PubMed] [Google Scholar]
  48. Schlienger K., Montefiori D. C., Mancini M., Rivière Y., Tiollais P., Michel M. L. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol. 1994 Oct;68(10):6578–6588. doi: 10.1128/jvi.68.10.6578-6588.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Siebelink K. H., Tijhaar E., Huisman R. C., Huisman W., de Ronde A., Darby I. H., Francis M. J., Rimmelzwaan G. F., Osterhaus A. D. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol. 1995 Jun;69(6):3704–3711. doi: 10.1128/jvi.69.6.3704-3711.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Strijbosch L. W., Does R. J., Buurman W. A. Computer aided design and evaluation of limiting and serial dilution experiments. Int J Biomed Comput. 1988 Dec;23(3-4):279–290. doi: 10.1016/0020-7101(88)90020-7. [DOI] [PubMed] [Google Scholar]
  51. Takahashi H., Takeshita T., Morein B., Putney S., Germain R. N., Berzofsky J. A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature. 1990 Apr 26;344(6269):873–875. doi: 10.1038/344873a0. [DOI] [PubMed] [Google Scholar]
  52. Venet A., Bourgault I., Aubertin A. M., Kiény M. P., Levy J. P. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. J Immunol. 1992 May 1;148(9):2899–2908. [PubMed] [Google Scholar]
  53. Venet A., Walker B. D. Cytotoxic T-cell epitopes in HIV/SIV infection. AIDS. 1993;7 (Suppl 1):S117–S126. [PubMed] [Google Scholar]
  54. Yasutomi Y., Koenig S., Woods R. M., Madsen J., Wassef N. M., Alving C. R., Klein H. J., Nolan T. E., Boots L. J., Kessler J. A. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol. 1995 Apr;69(4):2279–2284. doi: 10.1128/jvi.69.4.2279-2284.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. de Vries P., Heeney J. L., Boes J., Dings M. E., Hulskotte E. G., Dubbes R., Koornstra W., ten Haaft P., Akerblom L., Eriksson S. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine. 1994 Nov;12(15):1443–1452. doi: 10.1016/0264-410x(94)90154-6. [DOI] [PubMed] [Google Scholar]
  56. van Baalen C. A., Klein M. R., Geretti A. M., Keet R. I., Miedema F., van Els C. A., Osterhaus A. D. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS. 1993 Jun;7(6):781–786. [PubMed] [Google Scholar]
  57. van Binnendijk R. S., van Baalen C. A., Poelen M. C., de Vries P., Boes J., Cerundolo V., Osterhaus A. D., UytdeHaag F. G. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J Exp Med. 1992 Jul 1;176(1):119–128. doi: 10.1084/jem.176.1.119. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES